Le Lézard
Classified in: Health, Science and technology, Business

Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia

Egret Therapeutics, a portfolio company of Turret Capital Management, announces FDA Clearance of its IND Application for EGT 101

NEW YORK, Feb. 4, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EGT 101 that is being studied for the treatment of Delayed Cerebral Ischemia (DCI) following aneurysmal subarachnoid hemorrhage. The Phase I/II trial is expected to begin enrolling patients in 2023.

"We are thrilled to have received IND clearance for our program in aneurysmal subarachnoid hemorrhage," said Daniel Chai, M.D., Co-Founder and Chief Executive Officer of Egret Therapeutics. "Clearance of this IND is a testament to the hard work and deep commitment from the Egret team in bringing drugs to the market that will help patients," said Henry Park, Chief Financial Officer of Egret Therapeutics.

Among subarachnoid hemorrhage (SAH) patients who survive the initial bleed of a ruptured aneurysm, delayed cerebral ischemia (DCI) is the most important preventable cause of mortality and poor neurological outcome. "DCI prevention has been the focus of SAH research for decades, but few clinical options exist today. We are excited to move forward in our clinical development of EGT 101 with the hopes of bringing a therapy to patients where there is a high unmet need," said Chris Jackson, M.D., Co-Founder and Chief Medical Officer of Egret Therapeutics.

About Egret Therapeutics

Egret Therapeutics is a clinical-stage biotherapeutics company. The company is focused on developing products to address areas of clinical unmet need in neurological diseases. 

For more information, visit us at www.egrettherapeutics.com




SOURCE Turret Capital Management

These press releases may also interest you

at 03:49
On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, hereinafter referred to as the "Company") released its annual financial results for 2022. During the reporting period, the Company's operating revenue increased by 87.8% YOY...

at 03:46
LightInTheBox Holding Co., Ltd. ("LightInTheBox" or the "Company"), a global online retail company that delivers products directly to consumers around the world, announced that: (i)      Zhi Yan ("Mr. Yan") has resigned as the chairman of the board...

at 03:35
Securin Inc. and Ivanti have conducted an investigation into the cyber hygiene of Indian state government domains and found several potential gaps in their current security practices. The investigation used the Securin Attack Surface Management...

at 03:29
Waton Securities International Limited (also known as Waton or Waton International) is a premier brokerage service provider, established in 1989 with its headquarters in Hong Kong. With an R&D team located in Mainland China and offices across the...

at 03:21
Yankee Global Enterprises today announced the signing of a preliminary term sheet to acquire an equity stake in A1 Padel, the international, innovative padel circuit tour launched in 2020. Padel is one of the fastest growing sports in the world....

at 03:16
Research from global mobile trade association the GSMA estimates that the market for virtual network slicing among enterprises is projected to be worth USD$300bn by 2025. However, mobile operators who are seeking to use their 5G networks to offer...

News published on 4 february 2023 at 14:56 and distributed by: